Trump administration to trial Medicare, Medicaid coverage for obesity drugs: WaPO

14 hours ago 1

Healthcare

Comment
(1)

Obesity drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) traded higher in the premarket on Friday after The Washington Post reported that the Trump Administration plans to cover weight loss drugs for some Medicare and Medicaid enrollees

Recommended For You

Read Entire Article

Trump administration to trial Medicare, Medicaid coverage for obesity drugs: WaPO

Recommended For You

Related

Nexa signals higher second-half EBITDA and stable guidance a...

Cavco Industries signals continued production ramp and Ameri...

American Homes 4 Rent raises 2025 Core FFO guidance to $1.86...

The friendship premium: A majority of people would trade 20%...

Ero Copper outlines sequential production improvement target...

Chevron targets $12.5B free cash flow in 2026 with Hess inte...

Camden Property Trust signals 4%–5% rent growth in 2026–2027...

Crude oil sinks on soft U.S. jobs data, OPEC+ expectations b...

After firing labor stats head, Trump calls on Powell to resi...

Cooper-Standard targets 6% sealing and 8% fluid business rev...

Boeing sued by Alaska Airlines flight attendants over mid-ai...

Liberty Global signals strategic asset separation within 12–...

Silvercrest signals robust $200M actionable pipeline while e...

Cboe raises 2025 organic net revenue growth guidance to high...

Ichor Holdings Q2 2025 Earnings Preview

Ryman Hospitality Properties Q2 2025 Earnings Preview

FreightCar America Q2 2025 Earnings Preview

Syndax Pharmaceuticals Q2 2025 Earnings Preview

Inspire Medical Systems Q2 2025 Earnings Preview

Scienture files $200M mixed securities shelf

Trending

Popular

صدور هشدار زرد هواشناسی در چهارمحال و بختیاری

تصویری پربازدید از مجسمه پاندای کونگ‌فو کار